ARG1 and metastatic neoplasm: Of note, even in advanced metastatic tumors (d14), MerTKi treatment reduced Arg1 expression in MoMs (Extended Data Fig. 4l) without affecting overall abundance of MoMs (Extended Data Fig. 4m,n).